Progressive ROS1-Altered Advanced NSCLC
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

Released: September 05, 2024

Expiration: September 04, 2025

Jessica J Lin
Jessica J Lin, MD
Alice Shaw
Alice Shaw, MD, PhD

Activity

Progress
1
Course Completed

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

  • Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
  • Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases    
  • Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
  • The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC